Bartlett & Co’s Kronos Bio KRON Stock Holding History

Bartlett & Co’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4	Closed	–	–	1046
2021 Q1	$0	Hold	4	–	–	﹤0.01%	1118
2020 Q4	$0	Buy	+4	New	+$125	﹤0.01%	1172

Other funds holding KRON

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bartlett & Co's KRON Position: Q2 2021 in Review

Bartlett & Co sold out of Kronos Bio (KRON) in Q2 2021, closing a stake of 4 shares.

Bartlett & Co first reported a position in KRON in Q4 2020 and held it in 2 quarters. The position peaked at $0 in Q1 2021. 77 funds tracked by Wall St. Rank hold KRON as of Q2 2021.

Bartlett & Co reported no remaining Kronos Bio position as of Q2 2021 after selling out during the quarter.
Bartlett & Co sold 4 Kronos Bio shares in Q2 2021.
Bartlett & Co first reported a position in Kronos Bio in Q4 2020 and held it in 2 quarters.
Bartlett & Co's Kronos Bio position peaked at $0 in Q1 2021.
77 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2021.

Based on Bartlett & Co's 13F filing for Q2 2021, filed 19 Jul 2021.